Item Type | Name |
Concept
|
Protein Kinase C-delta
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
Concept
|
Protein Kinase C
|
Concept
|
CDC2 Protein Kinase
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
Concept
|
Protein Kinase C-alpha
|
Concept
|
Protein Kinase Inhibitors
|
Concept
|
Proto-Oncogene Proteins c-akt
|
Academic Article
|
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
Academic Article
|
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells.
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
Academic Article
|
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
|
Academic Article
|
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
|
Academic Article
|
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
|
Academic Article
|
c-Met inhibition.
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
Role of c-Met in cancer: emphasis on lung cancer.
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
Academic Article
|
Fyn: a novel molecular target in cancer.
|
Academic Article
|
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
|
Academic Article
|
A novel classification of lung cancer into molecular subtypes.
|
Academic Article
|
Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
|
Academic Article
|
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
Academic Article
|
Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
Academic Article
|
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
Academic Article
|
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
Academic Article
|
Novel targets for therapeutic agents in small cell lung cancer.
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
Academic Article
|
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.
|
Academic Article
|
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
Academic Article
|
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
|
Academic Article
|
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
|
Academic Article
|
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
Academic Article
|
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
|
Academic Article
|
FAK and paxillin, two potential targets in pancreatic cancer.
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
Academic Article
|
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
Academic Article
|
Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
Academic Article
|
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
|
Academic Article
|
Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.
|
Academic Article
|
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
|
Academic Article
|
MET receptor in oncology: From biomarker to therapeutic target.
|
Academic Article
|
Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.
|
Academic Article
|
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
Academic Article
|
Activating p53 function by targeting RLIP.
|
Academic Article
|
Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP.
|
Academic Article
|
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
|
Concept
|
Protein Kinase C beta
|
Academic Article
|
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
|
Academic Article
|
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
|